Skip to main content
European Commission logo print header

Novel nanomedicine for the treatment of glioma

Project description

New approach for the treatment of high-grade gliomas

High-grade gliomas (HGG) are the most aggressive brain cancer. The prognosis for patients with HGG is poor, and the most effective treatment, radiotherapy, increases median survival by only a few months. The Italian SME Lisapharma aims to develop a new treatment for HGG, including glioblastoma multiforme, based on a nanotechnology platform. The medicinal product comprises a dispersion for injection containing patented nanoparticles loaded with zoledronic acid as an active ingredient. Compared to current brain cancer treatments, this product demonstrated significant improvements with higher efficacy and lower toxicity in animal models. The objective of the EU-funded EDROMA project is to finalise the product and develop a business plan for its introduction to the market.


Lisapharma, an Italian pharmaceutical SME, aims to bring on the market Edroma: a new product based on a nanotechnology platform to treat malignant high-grade gliomas (HGG), for which there are no satisfactory curative methods. High-grade gliomas are the most aggressive type of brain cancer. Despite recent advances in treatment, the prognosis for patients with HGG is dismal: so far the most effective treatment, radiotherapy, brings an increase in median survival from 3-4 months to around 9-10. The Edroma medicinal product is a dispersion for injection made of nanoparticles encapsulating the active ingredient zoledronic acid, resulting by a self-assembling procedure made possible by Lisapharma’s patented platform. Compared to the current brain-cancer therapy solutions, Edroma innovation brings significant improvements in terms of higher efficacy and lower toxicity. Pre-clinical tests on mice demonstrated tumour reduction, increased life-expectancy and even, in one case out of 6, complete cure. Lisapharma has obtained the orphan designation from both EMA and FDA. This represents a unique business opportunity, as Lisapharma will be the only authorised provider of the new product for 10 year (7 in USA). It is estimated that the number of treatable cases in EU and USA could reach 20,000 subjects for which there are no alternative curative therapy. Considering 15,000 € per treatment cycle, the values of this potential market approximate 135 M€, and Lisapharma intends to reach 30% of this market in 5 years. The project has the potential to boost growth of Lisapharma by increasing significantly the company turnover. The total investment required is about 4.5 M€ over 3 years, for clinical studies, equipment and industrialisation, marketing and business development, with a foreseen ROI (internal return rate) of 122%.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
Via licinio 11
22036 Erba

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Nord-Ovest Lombardia Como
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00